Archive: Company News
Evonik and BellaSeno advance commercialization of 3D-printed, bioresorbable implants
— Expanded partnership of two leading innovators
— Resomer® used in commercial 3D-printed implants for both soft and hard tissue applications
— BellaSeno receives market authorization for fully resorbable implants – custom-made with Resomer®
Essen and Leipzig, Germany. Evonik and BellaSeno, a developer of 3D-printed absorbable scaffolds, are working together to commercialize innovative 3D-printed scaffolds for bone regeneration. The bone scaffolds are made with Evonik’s Resomer® polymers and are used for large and complex bone defects. Both companies initially began collaborating in 2019 on scaffolds for chest wall and breast reconstruction.
Pan Cancer T Appoints Prof. Dr. Chiara Bonini to its Scientific Advisory Board
– Leading European T cell therapy researcher adds further scientific expertise
Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announced the appointment of Prof. Dr. Chiara Bonini to its Scientific Advisory Board.
Prof. Dr. Chiara Bonini is Professor of Hematology at the Università Vita-Salute San Raffaele, School of Medicine, and Deputy Director of the Research Division of Immunology, Transplantation and Infectious Diseases at the San Raffaele Scientific Institute (Milan, Italy). Read more…
Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor
— Claus Andersson, PhD, joins Rewind´s Board of Directors
Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that it has raised additional funding, with Sunstone Life Science Ventures A/S joining as a new investor and with participation of existing investors Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven.
Claus Andersson, PhD, General Partner at Sunstone Life Science Ventures A/S, will join Rewind Therapeutics´ Board of Directors. Financial details of the transaction were not disclosed.
ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002
– Lead compound IOS-1002 to be studied as mono and combination therapy in patients with advanced solid tumors
– First patients to be enrolled in Q1, 2023
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that the Company has received full ethical institutional approval from the Human Research Ethics Committee (HREC) and regulatory approval from the Therapeutic Goods Administration (TGA) to conduct a Phase 1 trial of its lead program IOS-1002 in Australia. The first patients are expected to be enrolled in Q1, 2023.